TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Primary Objective
• To evaluate the pharmacodynamic effects on metabolic endpoints (malonyl carnitine and
tripalmitin levels) following short-term treatment with TVB-2640 in patients with resectable
cancers
Secondary Objectives
- To determine if short-term treatment with TVB-2640 decreases cancer cell proliferation.
- To examine other biological endpoints and determine if TVB-2640 inhibits cell survival
signaling and lipid biogenesis.
- To perform comprehensive metabolomic analysis in tumor tissues to identify metabolic
alterations induced by TVB-2640 treatment.
- To correlate FASN levels in tumor with metabolic and biological endpoints to determine
if FASN inhibition has more pronounced effects in patients with increased expression.